PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.

Date publication

avril 2023

Journal

Gynecologic oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MANSI Laura , Dr FAVIER Laure

Tous les auteurs :
Gauduchon T, Kfoury M, Lorusso D, Floquet A, Ventriglia J, Salaun H, Moubarak M, Rivoirard R, Polastro L, Favier L, You B, Berton D, de la Motte Rouge T, Mansi L, Abdeddaim C, Prulhiere K, Lancry Lecomte L, Provansal M, Dalban C, Ray-Coquard I

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37105063

Résumé

PARP inhibitors (PARPi) have revolutionized the management of high-grade epithelial ovarian cancer (HGOC) treatment. However, a significant number of patients relapse or progress under PARPi, leading to the introduction of a new line of systemic therapy such as chemotherapy. In patients with a limited number of metastatic sites at progression, -referred to as an oligometastatic progression- a potential indication for local therapy followed by re-introduction or continuation of PARPi treatment rather than initiating a new line of chemotherapy could be proposed. However, the impact of such strategies on progression free survival (PFS) in these patients remains unknown.

Mots clés

High-grade epithelial ovarian cancer, Local therapy, Oligometastatic progression, PARP inhibitors

Référence

Gynecol Oncol. 2023 04 25;173:98-105